5th Apr 2016 10:11
Cathay International Holdings Limited
("Cathay", the "Company")
Appointment of a Director
Hong Kong, 5 April 2016 - Cathay International Holdings Ltd. (LSE: CTI.L), a leading operator and investor in the growing healthcare sector in the People's Republic of China, is pleased to announce the appointment of Dr. Chan Ching Har Eliza, JP, BBS, LL.D. (Hon), as an independent non-executive director of the Company on 29 March 2016.
Dr. Chan is a Senior Consultant of Zhong Lun Law Firm. She is a Member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC), a Standing Member of the CPPCC Tianjin Committee, Foreign Economic Affairs Legal Counsel to the Tianjin Municipal People's Government, and an arbitrator of the China International Economic and Trade Arbitration Commission (CIETAC).
Dr. Chan serves as Chairman of Tseung Kwan O Hospital, Chairman of Pensions Appeal Panel, Member of the Administrative Appeals Board, Investigation Panel Member of the Hong Kong Institute of Certified Public Accountants and the Legal Advisor to The Hong Kong Chinese Enterprises Association. She is also the Chairman of the Hong Kong CPPCC (Provincial) Members Association Limited, Chairman of the Hong Kong CPPCC (Provincial) Members Foundation Limited, Honorary President of The Hong Kong China Chamber of Commerce and a Governor of The Canadian Chamber of Commerce in Hong Kong.
She was also formerly a Member of the Hong Kong Hospital Authority, Chairman of Kowloon Hospital, Chairman of Hong Kong Eye Hospital, Member of the Hong Kong Public Service Commission, Member of the Board of Education, Member of the Hong Kong Examination and Assessment Authority, Member of the Medical Council of Hong Kong, Member of Hospital Governing Committee of Queen Elizabeth Hospital, Council Member of The Hong Kong University of Science and Technology, Member of the Hong Kong Immigration Tribunal and Member of the Board of the Hong Kong Science and Technology Park Corporation.
Dr. Chan holds B.Sc (1979) from University of British Columbia, LL.B (1982) and LL.D (Hon)(2008) both from University of Victoria.
DETAILS OF PRESENT DIRECTORSHIPS | ||||
From | To | Company | Country of incorporation | Role |
Oct 2009 | Present | Tianjin International Holdings Limited | Hong Kong Listed | Non-executive Director |
March 2001 | Present | Concord International Investment Ltd. | Hong Kong Private | Director |
June 1993 | Present | Pacific Concord Holdings Ltd. | British Virgin Islands Private | Director |
Present | University of Victoria (Hong Kong) Foundation Limited | Hong Kong Private | Director | |
About 2006 | Present | Hong Kong CPPCC (Provincial) Members Association Ltd. | Hong Kong Company limited by guarantee | Director |
Present | Hong Kong CPPCC (Provincial) Members Foundation Ltd. | Hong Kong Private | Director | |
DETAILS OF PAST DIRECTORSHIPS IN THE LAST 5 YEARS | ||||
26 March 2012 | China Aerospace International Holdings Limited | Hong Kong Listed | Non-executive director | |
July 1999 | June 2015 | Hong Kong Science & Technology Corporation | Hong Kong Statutory body | Director |
Dec 2015 | Acudate Investments Ltd. | Hong Kong Private | Director |
-ENDS-
For further enquiries, please contact:
Cathay International Holdings Limited
Patrick Sung (Director and Controller)
Rebecca Yip (Company Secretary)
Tel: +852 2828 9289
N+1 Singer
+44 (0) 20 7496 3000
Aubrey Powell / Lauren Kettle - Corporate Finance
Brough Ransom - Sales
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Neal / Lindsey Neville
Tel: +44 (0) 20 3709 5702
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.
Related Shares:
CTI.L